보고서 요약(국문)

개요
전 세계 당뇨병성 위마비 치료 시장은 2022년 31억 달러 규모에 도달했으며, 2023년부터 2030년까지 연평균 3.8%의 성장률을 보이며 2030년에는 42억 달러에 이를 것으로 예상됩니다. 개인 맞춤형 의학으로의 전환, 즉 개별 질병 특성에 맞춘 치료가 가능해짐에 따라 전 세계 당뇨병성 위마비 치료 시장 성장을 주도할 것으로 전망됩니다.
또한, 당뇨병 유병률 증가, 전 세계적인 고령 인구 증가, 진단 기술 및 치료법의 발전, 그리고 임상 시험 건수 증가 등이 당뇨병성 위마비 치료 시장 규모 확대를 견인하고 있습니다.
특히 북미 지역에서는 당뇨병성 위마비 치료 접근법을 활용한 질병 치료 연구 활동의 증가와 주요 제약 회사들의 존재가 수요 증가의 주요 요인으로 작용하고 있습니다. 이 시장에는 EVOKE PHARMA, ANI Pharmaceuticals, Inc., Janssen Pharmaceutica N.V. 등의 주요 경쟁 업체들이 활발하게 활동하고 있습니다.

시장 동향
고령 인구 증가가 당뇨병성 위마비 치료 시장 성장을 견인할 전망
고령 인구 증가는 전 세계 당뇨병성 위마비 시장의 주요 성장 동력입니다. 당뇨병은 고령층에서 점점 더 흔해지고 있으며, 이로 인해 위마비 사례도 증가하고 있습니다. 예를 들어, 세계보건기구(WHO)의 2022년 보고서에 따르면 2030년에는 전 세계 인구 6명 중 1명이 60세 이상이 될 것으로 예상됩니다. 2030년에는 60세 이상 인구가 2020년 10억 명에서 14억 명으로 증가할 것입니다.
또한 2050년에는 60세 이상 인구가 두 배로 증가하여 21억 명에 이를 것으로 전망됩니다. 2020년에서 2050년 사이에 80세 이상 인구는 세 배로 증가하여 4,260억 명에 이를 것으로 예상됩니다. 이러한 연령 관련 위험 증가는 당뇨병성 위마비 진단 도구, 치료 및 요법에 대한 수요를 크게 증가시킵니다. 따라서 고령 인구가 증가할 것으로 예상됨에 따라 당뇨병성 위마비 치료 시장은 예측 기간 동안 성장할 것입니다.
새로운 치료법의 등장이 당뇨병성 위마비 치료 시장 성장을 견인할 것입니다.
새로운 치료법이 당뇨병성 위마비 치료 시장 성장을 견인할 것으로 예상됩니다. 위마비 치료에는 다양한 약물이 있으며, 그중 일부는 위 근육을 자극하여 위 배출을 개선하도록 특별히 설계되었습니다. 렐라모렐린, 프루칼로프리드, 아프레피탄트는 유망한 세 가지 실험적 약물입니다. 렐라모렐린은 합성 펜타펩타이드 그렐린 수용체 작용제로, 제2형 당뇨병 환자에서 고형 위 배출을 증가시키는 동시에 위 배출 지연을 개선하는 것으로 나타났습니다.
예를 들어, 위장 운동 촉진제는 위 배출 개선에 도움이 될 수 있습니다. 연구자들은 개발 중인 신약인 벨루세트라그와 같은 위마비 치료를 위한 새로운 약물을 계속해서 찾고 있습니다. 또한, 에보크 파마(Evoke Pharma)는 2020년에 FDA가 급성 및 재발성 당뇨병성 위마비 환자의 증상 치료를 위한 기모티(Gimoti) 비강 스프레이의 신약 승인을 받았다고 밝혔습니다. 따라서 위의 요인들로 인해 시장은 예측 기간 동안 성장할 것으로 예상됩니다.
FDA 승인 당뇨병성 위마비 치료제의 부족은 시장 성장을 저해할 것입니다.
당뇨병성 위마비의 치료 또는 관리를 위해 특별히 개발된 FDA 승인 의약품이 부족한 것은 시장 확장을 크게 저해합니다. 이러한 규제 장벽은 승인되고 표준화된 의약품의 가용성을 제한하여 당뇨병성 위마비 환자의 치료 선택지를 줄입니다.
예를 들어, 현재 메토클로프라미드는 위마비 치료를 위해 FDA 승인을 받은 유일한 약물입니다. 그러나 메토클로프라미드는 당뇨병성 위마비에 특화하여 승인된 것이 아니라 일반적인 위마비 치료를 위해 승인된 것임을 이해해야 합니다. 돔페리돈과 같은 다른 약물들도 위마비 치료에 효과를 보였지만, 이 질환에 대한 FDA 승인을 받지는 못했습니다. 따라서 위와 같은 요인들로 인해 시장은 향후 상당 기간 동안 제약을 받을 것으로 예상됩니다.
세분화 분석
전 세계 당뇨병성 위마비 치료 시장은 유형, 약물 종류, 투여 경로, 유통 채널 및 지역별로 세분화됩니다.
우수한 효과 덕분에 위장 운동 촉진제 부문이 당뇨병성 위마비 치료 시장 점유율의 약 34.6%를 차지했습니다.
위장 운동 촉진제는 위장 운동성을 향상시키는 효과가 뛰어나 당뇨병성 위마비 치료 시장을 주도할 것으로 예상됩니다. 도파민-2(D2) 수용체 길항제인 메토클로프라미드는 당뇨병성 위마비에 대한 FDA 승인을 받지는 않았지만, 위마비 치료에 있어 1차 치료제로 여겨지고 있습니다. 대부분의 국가에서 위마비 치료에 승인되거나 사용 가능한 약물은 메토클로프라미드와 돔페리돈 두 가지뿐입니다.
하지만 위운동촉진제를 이용한 당뇨병성 위마비 치료 임상시험이 점차 증가하고 있습니다. 예를 들어, 신돔파마(CinDome Pharma, Inc.)는 당뇨병성 위마비 성인 환자를 대상으로 CIN-102(듀돔페리돈)의 효능과 안전성을 평가하는 임상시험을 진행하고 있습니다. 현재 2상 임상시험이 진행 중이며, 2024년 10월 완료 예정입니다. 이처럼 위운동촉진제의 효과가 향상됨에 따라 향후 예측 기간 동안 해당 분야가 시장을 주도할 것으로 예상됩니다.

지리적 시장 침투
북미는 당뇨병 유병률 증가에 힘입어 2022년 시장 점유율 약 36.9%를 차지했습니다.
북미, 특히 미국은 이 지역에 주요 기업들이 다수 자리 잡고 있고, 당뇨병 유병률이 증가하고 있으며, 주요 기관들의 활발한 연구 활동과 새로운 치료법 개발로 인해 전 세계 당뇨병성 위마비 치료 시장을 주도하고 있습니다.
당뇨병 유병률 증가는 전 세계 당뇨병성 위마비 시장 성장의 주요 동인입니다. 당뇨병 진단 환자 수가 증가함에 따라 당뇨병성 위마비 발병 위험도 증가합니다. 당뇨병성 위마비는 고혈당으로 인해 위 근육과 위 운동을 돕는 카할 간질세포의 신경에 영향을 미칠 수 있기 때문입니다.

예를 들어, 미국 당뇨병 협회의 2022년 보고서에 따르면, 2019년 기준 약 373억 명의 미국인, 즉 인구의 11.3%가 당뇨병을 앓고 있었습니다. 20세 미만 미국인 중 약 28만 3천 명이 당뇨병 진단을 받았으며, 매년 14억 명의 미국인이 새로 당뇨병 진단을 받고 있습니다. 이러한 요인들로 인해 해당 지역은 예측 기간 동안 성장할 것으로 예상됩니다.
경쟁 환경
당뇨병성 위마비 치료 시장의 주요 글로벌 업체로는 EVOKE PHARMA, ANI Pharmaceuticals, Inc., Janssen Pharmaceutica N.V, Teva Pharmaceuticals Inc., Pfizer Inc., Salix Pharmaceuticals, Inc., Allergan, Novartis AG, SCHWITZ BIOTECH, Wellona Pharma 등이 있습니다.
COVID-19 영향 분석
COVID-19는 전 세계 당뇨병성 위마비 치료 시장에 상당한 영향을 미치고 있습니다. 코로나19는 중증급성호흡기증후군 코로나바이러스 2(SARS-CoV-2) 감염으로 발생하는 질환으로, 일반적으로 발열, 기침, 호흡곤란 등의 증상을 나타냅니다. 일부 환자는 폐 증상과 함께 또는 단독으로 위장관 증상을 경험한 후 SARS-CoV-2 양성 판정을 받습니다.
이는 위장관 SARS-CoV-2 감염 또는 호흡기 바이러스 질환의 전신적 영향 때문일 수 있습니다. 코로나19는 위마비와 같은 만성 위장관 질환을 앓고 있는 사람들에게 기존 질환의 악화를 유발할 수 있는데, 이는 바이러스가 위마비와 같은 만성 위장관 질환을 악화시키는 원인이 되어왔기 때문입니다. 따라서 코로나19는 당뇨병성 위마비 치료 시장에 큰 영향을 미칠 수 있습니다.

유형별
• 2등급
• 3등급
약물 분류별
• 위장 운동 촉진제
• 항구토제
• 항히스타민제
• 기타
투여 경로별
• 경구
• 주사제
• 비강 투여
유통 채널별
• 병원
• 소매 약국
• 온라인 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 스페인
o 이탈리아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 개발 사항
• 위장 질환 치료 전문 제약 회사인 Evoke Pharma, Inc.와 생명 과학 산업에 글로벌 상업 서비스를 제공하는 선도 기업인 EVERSANA는 2020년 10월 26일, 새로운 제품의 상용 출시를 발표했습니다. 성인의 급성 및 재발성 당뇨병성 위마비 증상 완화를 위한 기모티(메토클로프라미드) 비강 스프레이.
DMI 의견
전 세계 당뇨병성 위마비 치료 시장은 예측 기간 동안 성장할 것으로 예상됩니다. 이는 특정 질병 특성에 맞춘 맞춤형 치료에 대한 현재 추세에 의해 좌우됩니다. 이러한 시장 변화는 CRISPR-Cas9 및 RNA 간섭과 같은 신기술의 등장과 당뇨병 유병률 증가, 고령 인구 증가, 진단 및 치료의 발전, 임상 시험 증가와 같은 요인에 의해 촉진되고 있습니다.
특히 북미 지역에 주요 제약 회사와 경쟁업체가 존재하고 고령 인구가 증가하는 추세가 시장 성장을 견인하고 있습니다. 그러나 당뇨병성 위마비 치료를 위한 FDA 승인 의약품이 부족한 것은 여전히 한계로 작용합니다. 위장 운동 개선에 효과적인 위장 운동 촉진제 부문은 성장이 예상됩니다. 코로나19 팬데믹은 위장관 증상이 질병의 일부로 나타나고 위마비와 같은 기저 질환에 영향을 미칠 수 있다는 점에서 시장에 큰 영향을 미쳤습니다. 전반적으로 이러한 여러 요인과 추세로 인해 시장은 성장 잠재력을 가지고 있습니다.
보고서 구매 이유:

• 유형, 약물 종류, 투여 경로, 유통 채널 및 지역별 글로벌 당뇨병성 위마비 치료 시장 세분화를 시각화하고 주요 상업 자산 및 업체를 파악합니다.

• 트렌드 및 공동 개발 분석을 통해 사업 기회를 식별합니다.

• 모든 세그먼트를 포함한 당뇨병성 위마비 치료 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품 정보를 담은 엑셀 파일 형태의 제품 맵핑을 제공합니다.

글로벌 당뇨병성 위마비 치료 시장 보고서는 약 53개의 표, 54개의 그림, 195페이지 분량입니다.

2023년 목표 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Diabetic Gastroparesis Treatment Market reached US$ 3.1 billion in 2022 and is expected to reach US$ 4.2 billion by 2030 growing with a CAGR of 3.8% during the forecast period 2023-2030. The trend such as the shift towards personalized medicine enabling individual disease characteristics specific treatment is expected to dominate the global diabetic gastroparesis treatment market.
Furthermore, the rising prevalence of diabetes, increasing geriatric population around the globe, advancements in diagnostic technologies and treatment, and increasing number of clinical trials are driving up the diabetic gastroparesis treatment market size.
The growing research activities for treating disease using diabetic gastroparesis treatment approach and presence of establish pharmaceutical companies are some of the factors in demand from North America regions. With significant competitors EVOKE PHARMA, ANI Pharmaceuticals, Inc., Janssen Pharmaceutica N.V, and others actively operating in the market.
Dynamics
The Increasing Number of Geriatric Population to Drive the Growth of the Diabetic Gastroparesis Treatment Market
The growing elderly population is a major driving force in the worldwide diabetic gastroparesis market. Diabetes is becoming more prevalent in older population, thus leading gastroparesis cases. For instance, according to World Health Organization 2022 report, 1 out of 6 people in the world will be aged 60 years or over by 2030. At this point, the population aged 60 and up will climb from 1 billion in 2020 to 1.4 billion.
Moreover by 2050, the world's population of persons aged 60 and up will have doubled (2.1 billion). Between 2020 and 2050, the number of people aged 80 and more is expected to treble, reaching 426 Billion. This age-associated risk significantly contributes to the demand for diagnostic tools, treatments, and therapies for diabetic gastroparesis. Thus, as the geriatic population nmuber is expected to grow the market for diabetic gastroparesis treatment will drive over the forecast period.
The Emergence of New Therapies will Drive the Diabetic Gastroparesis Treatment Market Growth
Emerging therapies are predicted to drive diabetic gastroparesis treatment. There are various drugs available to treat gastroparesis, some of which are specially designed to stimulate the stomach muscles in order to improve gastric emptying. Relamorelin, prucalopride, and aprepitant are three promising experimental pharmacologic medicines. Relamorelin is a synthetic pentapeptide ghrelin receptor agonist that has been demonstrated to increase solid gastric emptying in type 2 diabetes patients while also demonstrating delayed gastric emptying.
Prokinetic drugs, for example, can aid improve stomach emptying. Researchers are continuing to look for novel drugs to treat gastroparesis, such as Velusetrag, a new drug under development. Furthermore, Evoke Pharma stated in 2020 that the FDA approved a new medication application for Gimoti nasal spray to treat symptoms in people with acute and recurrent diabetic gastroparesis. Thus, owing to the above factors the market is expected to drive over the forecast period.
The Lack of FDA Approved Therapies for Diabetic Gastroparesis Treatment Will Hamper the Growth of the Market.
The lack of FDA-approved medications specifically intended for the treatment or management of diabetic gastroparesis hampers market expansion significantly. This regulatory barrier restricts the availability of approved and standardized medicines, reducing treatment options for diabetic gastroparesis patients.
For instance, currently metoclopramide is the only FDA approved drug to treat gastroparesis . However, it is necessary to understand that metoclopramide is not approved specifically for diabetic gastroparesis, but rather for gastroparesis in general. Other drugs, such as domperidone, have showed promise in treating gastroparesis but are not FDA-approved for this specific illness. Thus, owing to the above factors the market is expected to face a restraint over the foreseeable future.
Segment Analysis
The global diabetic gastroparesis treatment market is segmented based on type, drug class, route of administration, distribution channel, and region.
Owing to the Better Effectiveness, the Gastroprokinetic Agents Segment Accounted for Approximately 34.6% of the Diabetic Gastroparesis Treatment Market Share
The gastroprokinetic agents segment is poised to dominate the diabetic gastroparesis treatment market due to effectiveness in enhancing the gastrointestinal motility and are used to treat gastroparesis. Metoclopramide a dopamine-2 (D2) receptors antagonist is the treatment of choice for gastroparesis, despite not being FDA approved for diabetic gastroparesis specifically, but it is still considered to be first line drug for treatment. In most countries, only two medications are approved or available for the treatment of gastroparesis are metoclopramide and domperidone.
Furthermore, the increasing number of clinical trial for treating diabetic gastroparesis employing gastroprokinetic agents is increasing. For instance, CinDome Pharma, Inc. is conducting a clinical trial to evaluate to evaluate the efficacy and safety of CIN-102 (Deudomperidone) in adults with diabetic gastroparesis. Currently the trial is in phase 2 and the estimated completion date for the trial is October 2024. Thus, due to gastroprokinetic agents better effectiveness the segment is expected to dominate over the forecast period.
Geographical Penetration
North America Accounted for Approximately 36.9% of the Market Share in 2022, Owing to the Rising Prevalence of Diabetes
North America, particularly the U.S., dominates the global diabetic gastroparesis treatment market due to presence of huge number of key players settled in the region, growing prevalence of diabetes, and high research activities along with developments of new therapies by major organization in the region.
The rising prevalence of diabetes is a major driver of the global diabetic gastroparesis market. As the number of people diagnosed with diabetes rises, it also increases the risk of diabetic gastroparesis. As in diabetic gastroparesis, hyperglycemia can affect stomach muscles and nerves of the interstitial cells of Cajal, which assist stomach muscles move.
For instance, according to American Diabetes Association report of 2022, approximately 37.3 Billion Americans, or 11.3% of the population had diabetes in 2019. About 283,000 people aging below 20 were diagnosed with diabetes in America. Furthermore, every year 1.4 Billion Americans are diagnosed with diabetes. Thus, owing to above factors the region is expected to grow over the forecast period.
Competitive Landscape
The major global players in the diabetic gastroparesis treatment market include EVOKE PHARMA, ANI Pharmaceuticals, Inc., Janssen Pharmaceutica N.V, Teva Pharmaceuticals Inc., Pfizer Inc., Salix Pharmaceuticals, Inc., Allergan, Novartis AG, SCHWITZ BIOTECH, Wellona Pharma, and among others.
COVID-19 Impact Analysis
The impact of COVID-19 on the global diabetic gastroparesis treatment market is significant. COVID-19, a condition caused by infection with the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), commonly appears as fever, cough, and shortness of breath. After experiencing gastrointestinal (GI) symptoms alone or in conjunction with lung symptoms, some patients tested positive for SARS-CoV-2.
This could be due to GI SARS-CoV-2 infection or a systemic effect of the respiratory viral illness. COVID-19 can appear as a flare of their underlying GI condition in individuals with chronic GI illnesses such as gastroparesis, as viruses have historically been involved in exacerbations of chronic GI disorders such as gastroparesis. Thereby creating a major impact on the diabetic gastroparesis treatment market.
By Type
• Grade 2
• Grade 3
By Drug Class
• Gastroprokinetic Agents
• Antiemetic Agents
• Anti-histamines
• Others
By Route of Administration
• Oral
• Parenteral
• Nasal
By Distribution Channel
• Hospitals
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• On October 26, 2020, Evoke Pharma, Inc., a specialty pharmaceutical company dedicated to GI disease treatments, and EVERSANA, a leading provider of global commercial services to the life science industry, are pleased to announce the commercial launch of Gimoti (metoclopramide) nasal spray for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis.
DMI Opinion
The Global Diabetic Gastroparesis Treatment Market is predicted to expand over the forecast period. It is defined by current trends toward personalized therapy adapted to specific disease characteristics. This market transformation is aided by the emergence of novel technologies such as CRISPR-Cas9 and RNA interference, as well as factors such as rising diabetes prevalence, a growing geriatric population, advancements in diagnostics and treatments, and increased clinical trials.
The presence of established pharmaceutical corporations and significant competitors, particularly in North America, drives the market, along with the growing elderly population. However, the lack of FDA-approved medicines for diabetic gastroparesis treatment remains a limitation. Because of its effectiveness in improving gastrointestinal motility, the Gastroprokinetic Agents segment is expected to grow. The COVID-19 pandemic has also had major effects on the market, with GI symptoms developing as part of the disease and potentially affecting underlying diseases such as gastroparesis. Overall, the market has the potential for growth as a result of these distinct dynamics and trends.
Why Purchase the Report?
• To visualize the global diabetic gastroparesis treatment market segmentation based on type, drug class, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of diabetic gastroparesis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.
The global diabetic gastroparesis treatment market report would provide approximately 53 tables, 54 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Drug Class
3.3. Snippet by Route of Administration
3.4. Snippet by Distribution Channel
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The Increasing Number of Geriatric Population
4.1.1.2. The Emergence of New Therapies
4.1.2. Restraints
4.1.2.1. The Lack of FDA Approved Therapies for Diabetic Gastroparesis Treatment
4.1.3. Opportunity
4.1.3.1. Increasing Demand for Personalized Medicine
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Grade 2*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Grade 3
8. By Drug Class
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.1.2. Market Attractiveness Index, By Drug Class
8.2. Gastroprokinetic Agents*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Antiemetic Agents
8.4. Anti-histamines
8.5. Others
9. By Route of Administration
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
9.1.2. Market Attractiveness Index, By Route of Administration
9.2. Oral*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Parenteral
9.4. Nasal
10. By Distribution Channel
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.1.2. Market Attractiveness Index, By Distribution Channel
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Retail Pharmacies
10.4. Online Pharmacies
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. U.K.
11.3.7.3. France
11.3.7.4. Spain
11.3.7.5. Italy
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. EVOKE PHARMA*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. ANI Pharmaceuticals, Inc.
13.3. Janssen Pharmaceutica N.V
13.4. Teva Pharmaceuticals Inc.
13.5. Pfizer Inc.
13.6. Salix Pharmaceuticals, Inc.
13.7. Allergan
13.8. Novartis AG
13.9. SCHWITZ BIOTECH
13.10. Wellona Pharma
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

EVOKE PHARMA, 4.	Key Developments, ANI Pharmaceuticals, Inc., Janssen Pharmaceutica N.V, Teva Pharmaceuticals Inc., Pfizer Inc., Salix Pharmaceuticals, Inc., Allergan, Novartis AG, SCHWITZ BIOTECH, Wellona Pharma

표 목록 (Tables)

List of Tables

Table 1 Global Diabetic Gastroparesis Treatment Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Diabetic Gastroparesis Treatment Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Diabetic Gastroparesis Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Diabetic Gastroparesis Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Diabetic Gastroparesis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Diabetic Gastroparesis Treatment Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 7 Global Diabetic Gastroparesis Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 8 Global Diabetic Gastroparesis Treatment Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Billion)

Table 9 Global Diabetic Gastroparesis Treatment Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 10 Global Diabetic Gastroparesis Treatment Market Value, By Route of Administration, 2022, 2026 & 2030 (US$ Billion)

Table 11 Global Diabetic Gastroparesis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 12 Global Diabetic Gastroparesis Treatment Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 13 Global Diabetic Gastroparesis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 14 Global Diabetic Gastroparesis Treatment Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 15 Global Diabetic Gastroparesis Treatment Market Value, By Region, 2021-2030 (US$ Billion)

Table 16 North America Diabetic Gastroparesis Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 17 North America Diabetic Gastroparesis Treatment Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 18 North America Diabetic Gastroparesis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 19 North America Diabetic Gastroparesis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 20 North America Diabetic Gastroparesis Treatment Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 South America Diabetic Gastroparesis Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 22 South America Diabetic Gastroparesis Treatment Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 23 South America Diabetic Gastroparesis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 24 South America Diabetic Gastroparesis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 25 South America Diabetic Gastroparesis Treatment Market Value, By Country, 2021-2030 (US$ Billion)

Table 26 Europe Diabetic Gastroparesis Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 27 Europe Diabetic Gastroparesis Treatment Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 28 Europe Diabetic Gastroparesis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 29 Europe Diabetic Gastroparesis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 30 Europe Diabetic Gastroparesis Treatment Market Value, By Country, 2021-2030 (US$ Billion)

Table 31 Asia-Pacific Diabetic Gastroparesis Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 32 Asia-Pacific Diabetic Gastroparesis Treatment Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 33 Asia-Pacific Diabetic Gastroparesis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 34 Asia-Pacific Diabetic Gastroparesis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 35 Asia-Pacific Diabetic Gastroparesis Treatment Market Value, By Country, 2021-2030 (US$ Billion)

Table 36 Middle East & Africa Diabetic Gastroparesis Treatment Market Value, By Type, 2021-2030 (US$ Billion)

Table 37 Middle East & Africa Diabetic Gastroparesis Treatment Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 38 Middle East & Africa Diabetic Gastroparesis Treatment Market Value, By Route of Administration, 2021-2030 (US$ Billion)

Table 39 Middle East & Africa Diabetic Gastroparesis Treatment Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 40 EVOKE PHARMA: Overview

Table 41 EVOKE PHARMA: Product Portfolio

Table 42 EVOKE PHARMA: Key Developments

Table 43 ANI Pharmaceuticals, Inc.: Overview

Table 44 ANI Pharmaceuticals, Inc.: Product Portfolio

Table 45 ANI Pharmaceuticals, Inc.: Key Developments

Table 46 Janssen Pharmaceutica N.V: Overview

Table 47 Janssen Pharmaceutica N.V: Product Portfolio

Table 48 Janssen Pharmaceutica N.V: Key Developments

Table 49 Teva Pharmaceuticals Inc.: Overview

Table 50 Teva Pharmaceuticals Inc.: Product Portfolio

Table 51 Teva Pharmaceuticals Inc.: Key Developments

Table 52 Pfizer Inc.: Overview

Table 53 Pfizer Inc.: Product Portfolio

Table 54 Pfizer Inc.: Key Developments

Table 55 Salix Pharmaceuticals, Inc.: Overview

Table 56 Salix Pharmaceuticals, Inc.: Product Portfolio

Table 57 Salix Pharmaceuticals, Inc.: Key Developments

Table 58 Allergan: Overview

Table 59 Allergan: Product Portfolio

Table 60 Allergan: Key Developments

Table 61 Novartis AG: Overview

Table 62 Novartis AG: Product Portfolio

Table 63 Novartis AG: Key Developments

Table 64 SCHWITZ BIOTECH: Overview

Table 65 SCHWITZ BIOTECH: Product Portfolio

Table 66 SCHWITZ BIOTECH: Key Developments

Table 67 Wellona Pharma: Overview

Table 68 Wellona Pharma: Product Portfolio

Table 69 Wellona Pharma: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Diabetic Gastroparesis Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 3 Global Diabetic Gastroparesis Treatment Market Share, By Drug Class, 2022 & 2030 (%)

Figure 4 Global Diabetic Gastroparesis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 5 Global Diabetic Gastroparesis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 6 Global Diabetic Gastroparesis Treatment Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Diabetic Gastroparesis Treatment Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 8 Grade 2 Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 9 Grade 3 Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 10 Global Diabetic Gastroparesis Treatment Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 11 Gastroprokinetic Agents Drug Class in Global Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 12 Antiemetic Agents Drug Class in Global Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 13 Anti-histamines Drug Class in Global Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 14 Others Drug Class in Global Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 15 Global Diabetic Gastroparesis Treatment Market Y-o-Y Growth, By Route of Administration, 2022-2030 (%)

Figure 16 Oral Route of Administration in Global Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 17 Parenteral Route of Administration in Global Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 18 Nasal Route of Administration in Global Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 19 Global Diabetic Gastroparesis Treatment Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 20 Hospital Pharmacies Distribution Channel in Global Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 21 Retail Pharmacies Distribution Channel in Global Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 22 Online Pharmacies Distribution Channel in Global Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 23 Global Diabetic Gastroparesis Treatment Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 24 North America Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 25 Asia-Pacific Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 26 Europe Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 27 South America Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 28 Middle East and Africa Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 29 North America Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 30 North America Diabetic Gastroparesis Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 31 North America Diabetic Gastroparesis Treatment Market Share, By Drug Class, 2022 & 2030 (%)

Figure 32 North America Diabetic Gastroparesis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 33 North America Diabetic Gastroparesis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 34 North America Diabetic Gastroparesis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 35 South America Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 36 South America Diabetic Gastroparesis Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 37 South America Diabetic Gastroparesis Treatment Market Share, By Drug Class, 2022 & 2030 (%)

Figure 38 South America Diabetic Gastroparesis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 39 South America Diabetic Gastroparesis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 40 South America Diabetic Gastroparesis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 41 Europe Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 42 Europe Diabetic Gastroparesis Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 43 Europe Diabetic Gastroparesis Treatment Market Share, By Drug Class, 2022 & 2030 (%)

Figure 44 Europe Diabetic Gastroparesis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 45 Europe Diabetic Gastroparesis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 46 Europe Diabetic Gastroparesis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 47 Asia-Pacific Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 48 Asia-Pacific Diabetic Gastroparesis Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 49 Asia-Pacific Diabetic Gastroparesis Treatment Market Share, By Drug Class, 2022 & 2030 (%)

Figure 50 Asia-Pacific Diabetic Gastroparesis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 51 Asia-Pacific Diabetic Gastroparesis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 52 Asia-Pacific Diabetic Gastroparesis Treatment Market Share, By Country, 2022 & 2030 (%)

Figure 53 Middle East & Africa Diabetic Gastroparesis Treatment Market Value, 2021-2030 (US$ Billion)

Figure 54 Middle East & Africa Diabetic Gastroparesis Treatment Market Share, By Type, 2022 & 2030 (%)

Figure 55 Middle East & Africa Diabetic Gastroparesis Treatment Market Share, By Drug Class, 2022 & 2030 (%)

Figure 56 Middle East & Africa Diabetic Gastroparesis Treatment Market Share, By Route of Administration, 2022 & 2030 (%)

Figure 57 Middle East & Africa Diabetic Gastroparesis Treatment Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 58 EVOKE PHARMA: Financials

Figure 59 ANI Pharmaceuticals, Inc.: Financials

Figure 60 Janssen Pharmaceutica N.V: Financials

Figure 61 Teva Pharmaceuticals Inc.: Financials

Figure 62 Pfizer Inc.: Financials

Figure 63 Salix Pharmaceuticals, Inc.: Financials

Figure 64 Allergan: Financials

Figure 65 Novartis AG: Financials

Figure 66 SCHWITZ BIOTECH: Financials

Figure 67 Wellona Pharma: Financials

세계 당뇨병성 위마비 치료 시장 – 2023-2030

Global Diabetic Gastroparesis Treatment Market - 2023-2030